BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sorin Group S.p.A. (SRN) Acquires Endoscopic Vessel Harvesting Business from Datascope, Inc. (DSCP)


2/10/2009 7:33:36 AM

MILAN--(BUSINESS WIRE)--Sorin Group (MIL:SRN) (Reuters code: SORN.MI), a global company and a leader in the treatment of cardiovascular diseases, announced today that it has acquired the Clearglide(R) endoscopic vessel harvesting product line of Datascope Inc. (NASDAQ: DSCP - News). Endoscopic vessel harvesting (‘EVH’) devices enable less-invasive harvesting of vessels for use in coronary artery bypass grafting. EVH procedures replace traditional open vessel harvesting, and avoid significant pain and discomfort for patients. In addition, the large incision that is required in an open vessel harvesting procedure is associated with a high rate of wound complications including dehiscence, hematoma and infection. The endoscopic approach is associated with fewer wound complications than the traditional open method.

"After conclusion in 2008 of our divestiture program, this transaction is a first step towards reinforcing our leading cardiac surgery franchises. This acquisition will be particularly exciting for Sorin Group’s United States business as it will reinforce our product offering and consolidate our position as the leading provider of innovative solutions for the cardiac surgery clinical community, ” said André-Michel Ballester, C.E.O. Sorin Group.

About the Sorin Group

The Sorin Group (www.sorin.com), is a global company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,500 employees worldwide, the Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over 1 million patients are treated with the devices of Sorin Group in more than 80 countries.

For more information, please visit: www.sorin.com.

Contact:

Martine Konorski Director, Corporate Communications Sorin Group Tel: +33 (0)1 46 01 33 78 Mobile: +33 (0)6 76 12 67 73 e-mail: martine.konorski@sorin.com or Carla Vidra Investor Relations Sorin Group Tel: +39 02 69969716 e-mail: carla.vidra@sorin.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES